Review



mouse normal liver hepatocyte cell line aml12  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC mouse normal liver hepatocyte cell line aml12
    Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or <t>AML12</t> ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001
    Mouse Normal Liver Hepatocyte Cell Line Aml12, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 264 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12%3B+Hepatocyte%3B+Mouse/pmc12334778-36-0-9
    Average 96 stars, based on 264 article reviews
    mouse normal liver hepatocyte cell line aml12 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties"

    Article Title: Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

    Journal: Discover Oncology

    doi: 10.1007/s12672-025-03380-8

    Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or AML12 ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001
    Figure Legend Snippet: Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or AML12 ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Techniques Used:

    Effect of IB/SB/SM on pro-fibrotic gene expression, antioxidant activity, and ALT concentration in AML12 cells. (A-C) Expression of pro-fibrotic genes fibronectin ( Fn1 ), smooth muscle actin ( Acta2 ) and collagen I ( Col1a1 ) after 24 h treatment with TGF-β1 (10 ng/mL) and IB/SB/SM (7.8–31.3 µg/mL) in AML12 cells. (D) Western blot analysis of fibronectin expression in AML12 cells stimulated for 24 h with TGF-β1 (10 ng/mL) and IB/SB/SM at concentration 31.3 µg/mL. Representative western blot bands are shown below the graphs. (E) DPPH antioxidant activity assay. The ability of IB/SB/SM to scavenge DPPH radicals was evaluated at various concentrations (0–500 µg/mL). (F) Determination of alanine aminotransferase (ALT) concentration in the supernatants of AML 12 cells stimulated with TGF-β1 (10 ng/mL) in the presence of the tested compounds (IB, SB, SM) at different concentrations. All results are expressed as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0,001 (for western blot: vs. TGF-β1 control)
    Figure Legend Snippet: Effect of IB/SB/SM on pro-fibrotic gene expression, antioxidant activity, and ALT concentration in AML12 cells. (A-C) Expression of pro-fibrotic genes fibronectin ( Fn1 ), smooth muscle actin ( Acta2 ) and collagen I ( Col1a1 ) after 24 h treatment with TGF-β1 (10 ng/mL) and IB/SB/SM (7.8–31.3 µg/mL) in AML12 cells. (D) Western blot analysis of fibronectin expression in AML12 cells stimulated for 24 h with TGF-β1 (10 ng/mL) and IB/SB/SM at concentration 31.3 µg/mL. Representative western blot bands are shown below the graphs. (E) DPPH antioxidant activity assay. The ability of IB/SB/SM to scavenge DPPH radicals was evaluated at various concentrations (0–500 µg/mL). (F) Determination of alanine aminotransferase (ALT) concentration in the supernatants of AML 12 cells stimulated with TGF-β1 (10 ng/mL) in the presence of the tested compounds (IB, SB, SM) at different concentrations. All results are expressed as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0,001 (for western blot: vs. TGF-β1 control)

    Techniques Used: Gene Expression, Antioxidant Activity Assay, Concentration Assay, Expressing, Western Blot, Control

    Related Articles

    Cell Culture:

    Article Title: Biglycan Alleviates Age-Related Muscle Atrophy and Hepatocellular Senescence
    Article Snippet: To induce myogenic differentiation, the growth medium was changed to DMEM supplemented with 2% horse serum (Gibco, Waltham, MA, USA) when the cells reached 80–90% confluence. .. AML12 mouse normal hepatocytes (ATCC, Manassas, VA, USA) were cultured in DMEM/F12 (Gibco, Waltham, MA, USA) supplemented with 10% FBS, 1% penicillin/streptomycin, 5 μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL selenium, and 40 ng/mL dexamethasone. .. Doxorubicin (Dox, D1515), dexamethasone (Dex, D4902), and palmitic acid (PA, P5585) were purchased from Sigma-Aldrich (Saint Louis, MO, USA).

    Article Title: Biglycan Alleviates Age-Related Muscle Atrophy and Hepatocellular Senescence.
    Article Snippet: To induce myogenic differentiation, the growth medium was changed to DMEM supplemented with 2% horse serum (Gibco, Waltham, MA, USA) when the cells reached 80–90% confluence. .. AML12 mouse normal hepatocytes (ATCC, Manassas, VA, USA) were cultured in DMEM/F12 (Gibco, Waltham, MA, USA) supplemented with 10% FBS, 1% penicillin/streptomycin, 5 μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL selenium, and 40 ng/mL dexamethasone. .. Doxorubicin (Dox, D1515), dexamethasone (Dex, D4902), and palmitic acid (PA, P5585) were purchased from Sigma-Aldrich (Saint Louis, MO, USA).



    Similar Products

    96
    ATCC mouse normal liver hepatocyte cell line aml12
    Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or <t>AML12</t> ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001
    Mouse Normal Liver Hepatocyte Cell Line Aml12, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12%3B+Hepatocyte%3B+Mouse/pmc12334778-36-0-9
    Average 96 stars, based on 1 article reviews
    mouse normal liver hepatocyte cell line aml12 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    98
    ATCC mouse normal hepatocyte cell line aml12
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Mouse Normal Hepatocyte Cell Line Aml12, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pmc13060607-218-7-17
    Average 98 stars, based on 1 article reviews
    mouse normal hepatocyte cell line aml12 - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    98
    ATCC mouse normal hepatocytes aml12 cell line
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Mouse Normal Hepatocytes Aml12 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pm41895488-73-1-30
    Average 98 stars, based on 1 article reviews
    mouse normal hepatocytes aml12 cell line - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    98
    ATCC mouse normal hepatocytes aml 12
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Mouse Normal Hepatocytes Aml 12, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pm41839365-253-21-29
    Average 98 stars, based on 1 article reviews
    mouse normal hepatocytes aml 12 - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    98
    ATCC mouse normal hepatocytes
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Mouse Normal Hepatocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pmc12481285-134-16-22
    Average 98 stars, based on 1 article reviews
    mouse normal hepatocytes - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    98
    ATCC mouse immortalized normal hepatocyte cell line aml
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Mouse Immortalized Normal Hepatocyte Cell Line Aml, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pm40945091-78-1-11
    Average 98 stars, based on 1 article reviews
    mouse immortalized normal hepatocyte cell line aml - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    98
    ATCC aml12 mouse normal hepatocytes
    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, <t>AML12</t> cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.
    Aml12 Mouse Normal Hepatocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aml12+mouse+normal+hepatocytes/AML12/pm40943208-148-0-4
    Average 98 stars, based on 1 article reviews
    aml12 mouse normal hepatocytes - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    Image Search Results


    Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or AML12 ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Journal: Discover Oncology

    Article Title: Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

    doi: 10.1007/s12672-025-03380-8

    Figure Lengend Snippet: Effect of IB/SB/SM on cytotoxicity and cell cycle arrest of liver cells. A : Chemical structure of IB and SB (silybin A and silybin B in ratio 1:1). Cytotoxicity in Hepa1-6 ( B ), HepG2 ( C ) or AML12 ( D ) liver cells after 24 h treatment with IB/SB/SM. Changes in the cell cycle in Hepa1-6 ( E ), HepG2 ( F ), or AML12 ( G ) liver cells after 24 h treatment with 31.3 µg/mL of IB/SB/SM. H : Cell distribution of diploid cells in the phases of the cell cycle shown for IB (31.3 µg/mL). The data are given as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001

    Article Snippet: Mouse normal liver hepatocyte cell line AML12 (RRID: CVCL_0140, ATCC, USA) was cultivated in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, 1X Insulin-Transferrin-Selenium and 40 ng/mL dexamethasone.

    Techniques:

    Effect of IB/SB/SM on pro-fibrotic gene expression, antioxidant activity, and ALT concentration in AML12 cells. (A-C) Expression of pro-fibrotic genes fibronectin ( Fn1 ), smooth muscle actin ( Acta2 ) and collagen I ( Col1a1 ) after 24 h treatment with TGF-β1 (10 ng/mL) and IB/SB/SM (7.8–31.3 µg/mL) in AML12 cells. (D) Western blot analysis of fibronectin expression in AML12 cells stimulated for 24 h with TGF-β1 (10 ng/mL) and IB/SB/SM at concentration 31.3 µg/mL. Representative western blot bands are shown below the graphs. (E) DPPH antioxidant activity assay. The ability of IB/SB/SM to scavenge DPPH radicals was evaluated at various concentrations (0–500 µg/mL). (F) Determination of alanine aminotransferase (ALT) concentration in the supernatants of AML 12 cells stimulated with TGF-β1 (10 ng/mL) in the presence of the tested compounds (IB, SB, SM) at different concentrations. All results are expressed as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0,001 (for western blot: vs. TGF-β1 control)

    Journal: Discover Oncology

    Article Title: Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

    doi: 10.1007/s12672-025-03380-8

    Figure Lengend Snippet: Effect of IB/SB/SM on pro-fibrotic gene expression, antioxidant activity, and ALT concentration in AML12 cells. (A-C) Expression of pro-fibrotic genes fibronectin ( Fn1 ), smooth muscle actin ( Acta2 ) and collagen I ( Col1a1 ) after 24 h treatment with TGF-β1 (10 ng/mL) and IB/SB/SM (7.8–31.3 µg/mL) in AML12 cells. (D) Western blot analysis of fibronectin expression in AML12 cells stimulated for 24 h with TGF-β1 (10 ng/mL) and IB/SB/SM at concentration 31.3 µg/mL. Representative western blot bands are shown below the graphs. (E) DPPH antioxidant activity assay. The ability of IB/SB/SM to scavenge DPPH radicals was evaluated at various concentrations (0–500 µg/mL). (F) Determination of alanine aminotransferase (ALT) concentration in the supernatants of AML 12 cells stimulated with TGF-β1 (10 ng/mL) in the presence of the tested compounds (IB, SB, SM) at different concentrations. All results are expressed as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0,001 (for western blot: vs. TGF-β1 control)

    Article Snippet: Mouse normal liver hepatocyte cell line AML12 (RRID: CVCL_0140, ATCC, USA) was cultivated in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, 1X Insulin-Transferrin-Selenium and 40 ng/mL dexamethasone.

    Techniques: Gene Expression, Antioxidant Activity Assay, Concentration Assay, Expressing, Western Blot, Control

    ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, AML12 cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.

    Journal: Science Advances

    Article Title: SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth

    doi: 10.1126/sciadv.aec4368

    Figure Lengend Snippet: ( A ) Liver tumor tissues were collected from the HTVi model and clinical patients and subjected to untargeted metabolomic profiling for pathway enrichment. ( B ) Summarized SLC transporters for TCA cycle intermediates. ( C ) Forest plot showing the hazard ratios (HR) for multiple genes encoding SLC transporters of TCA cycle intermediates in HCC. The horizontal line represents the 95% confidence interval. ( D ) Heatmap of detectable SLC transporters for TCA cycle intermediates in heterogeneous primary liver cancer models generated by genome editing of cancer driver genes selected by mutational frequency from human HCC cohorts (PRJNA674008). ( E ) qPCR analysis to screen candidate SLC transporters for HCC progression based on the relative expression of SLC transporters in the HTVi model ( n = 4 for the control group and n = 5 for the model group), mouse HCC Hepa1-6 cells, AML12 cells, and MPHs ( n = 3 independent experiments). ( F ) Venn diagram showing the overlap of significantly differentially expressed SLC transporters in the HTVi model, mouse HCC Hepa1-6 cells, and normal hepatocytes (AML12 and MPHs). ( G and H ) SLC13A2 expression in liver tissues from HTVi, AAV-cMYC/nRAS, and STZ-HFD HCC model. The data are presented as means ± SEM. * P < 0.05; ** P < 0.01, two-tailed unpaired Student’s t test. Ctrl, control; n.d., not determined; NS, not significant.

    Article Snippet: The mouse HCC cell line Hepa1-6 and mouse normal hepatocyte cell line AML12 were obtained from the American Type Culture Collection as described previously ( ).

    Techniques: Metabolomic, Generated, Expressing, Control, Two Tailed Test